Clinical Trial Update: Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports the immunogenicity of a commercial batch of the JEV IC51 Japanese encephalitis vaccine up to 24 months after filling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• JEV IC51 (inactivated Japanese encephalitis vaccine IC51)

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Japanese Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2014-01-23